This month
AOD-9604 came off the FDA's Category 2 restricted list in April — and the wellness internet noticed immediately
Last month, on April 23, 2026, AOD-9604 was removed from the FDA Category 2 bulk drug substances list — the designation that had blocked licensed compounding pharmacies from preparing the peptide under physician supervision since 2023. The removal happened because the companies that originally nominated AOD-9604 for that list withdrew their nominations — a technical regulatory step that clears Category 2 status without conferring any new authorization or scientific endorsement. That distinction did not travel well. Wellness clinic newsletters, TikTok creators covering the peptide space, and forum posts across biohacking and recovery communities treated the April removal as a green light. Some framed it as a return to legality. Others described it as AOD-9604 being approved again. Neither reading is accurate. The compound is not on the FDA Category 1 bulk substances list, which is the designation that actually permits licensed compounding under physician prescription. Unlike BPC-157, TB-500, MOTS-c, and four other peptides now formally scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026, AOD-9604 does not have a review date. [NBC News](https://www.nbcnews.com/health/health-news/fda-peptides-weighs-loosen-restrictions-longevity-rfk-jr-rcna332011) covered the broader regulatory moment when the FDA signaled it would ease restrictions on compounded peptides — and even that coverage was clear: Category 2 removal is the start of a regulatory process, not its conclusion. AOD-9604 is in a regulatory gap right now. The internet celebration did not include the gap.
The actual biology
A C-terminal fragment of growth hormone engineered to separate fat metabolism from everything else GH does
Human growth hormone is a 191-amino acid protein that drives fat metabolism, linear growth, IGF-1 production, glucose handling, and tissue repair — all at once, through the same receptor interaction. That full biological profile is why exogenous GH raises concerns at pharmacological doses: it elevates IGF-1, can worsen insulin sensitivity, causes edema, and activates growth pathways broadly. AOD-9604 was designed to extract a single layer from that biology. It is a synthetic analog of the C-terminal fragment of hGH spanning approximately positions 177 to 191 — a region hypothesized to carry the lipolysis-stimulating signal of the full molecule without the growth-hormone-receptor-binding activity that drives everything else. The original mechanistic work, developed by Metabolic Pharmaceuticals in Australia beginning in the late 1990s, proposed that this fragment preferentially interacts with beta-3 adrenergic receptors in adipose tissue, stimulating fat breakdown without the endocrine spillover of full-length GH. The [PubMed literature trail for AOD-9604](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) documents where that mechanistic hypothesis travels — through animal models, in vitro studies, and eventually into human trials. In obese mice treated chronically, researchers documented increased fat oxidation and weight loss without IGF-1 elevation or glucose disruption. The biological argument is coherent. Whether it translated into meaningful clinical benefit in humans is the separate question the clinical program was built to answer.
What the internet says
The fat-burning GH fragment that sidesteps growth hormone's downsides — a narrative two decades older than TikTok
The current wave of AOD-9604 content frames the compound as a precision fat-loss tool: the fragment that delivers the metabolic benefits of growth hormone without IGF-1 elevation, insulin resistance, edema, or the concerns that surround high-dose exogenous GH. That pitch travels because the underlying safety argument is real. Across six Metabolic Pharmaceuticals clinical trials involving approximately 900 participants, AOD-9604 consistently produced no serious adverse events, no immunogenic responses, no meaningful IGF-1 changes, and no glucose disruption. Those findings are documented and not contested — the safety profile of the compound is among the cleaner results in the research-peptide clinical record. TikTok content as of May 2026 has positioned AOD-9604 explicitly against the GLP-1 drug class: framed as the peptide for people who do not want GLP-1 nausea, who want to preserve muscle during a weight-loss phase, or who are already on semaglutide and looking for a complementary fat-loss signal. The comparison is strategically legible given how saturated wellness content has become with GLP-1 coverage. What that comparison does not include is the pivotal clinical endpoint — the result that determined what Metabolic Pharmaceuticals did next with the compound.
What the data actually shows
Six clinical trials, one pivotal Phase 2b endpoint, and a development program closed in February 2007
Metabolic Pharmaceuticals ran a formal clinical development program for AOD-9604 that enrolled approximately 900 participants across six Phase I and Phase II studies. Early data generated legitimate interest. The Phase IIa trial at the 1 mg oral dose produced statistically significant differences in weekly weight loss compared to placebo — a result that justified a larger study and attracted clinical attention. The pivotal test was the Phase IIb OPTIONS trial, which randomized 502 adults with obesity to oral AOD-9604 at 0.25, 0.5, or 1 mg per day versus placebo for 24 weeks alongside supervised diet and exercise. The primary endpoint was not met. Weight loss in the AOD-9604 arms was not statistically significantly different from placebo. Development was terminated in February 2007. The [ClinicalTrials.gov registry for AOD-9604](https://clinicaltrials.gov/search?term=AOD-9604) carries the documentation of this program. The Phase IIa-to-IIb reversal — promising signal in the smaller trial, null result in the larger controlled study — is a recognized pattern in obesity drug development. It appears when a tightly controlled dietary and exercise co-intervention narrows the gap between active drug and placebo until the pharmacological signal disappears into statistical noise. The FDA decision to include AOD-9604 on the Category 2 list in 2023 reflected this clinical record, among other factors. The April 2026 Category 2 removal changed a regulatory status. It did not revise the clinical record.
Early human verdict
More clinical data than most research peptides — and a specific, documented null result in the pivotal trial
AOD-9604 carries the Early human evidence tier on PeptideFactCheck. That placement reflects that human trials genuinely happened, enrolled real participants, and produced analyzable data — it is not a compound making clinical claims on the basis of animal work alone. The tier also reflects that the most rigorous of those trials, the Phase IIb OPTIONS study with 502 participants over 24 weeks, failed to demonstrate the weight-loss benefit that would have supported continued development. That combination — more human trial data than most research peptides, a specific and documented null result in the pivotal study — puts AOD-9604 in an unusual position in May 2026. Most compounds discussed in the current wave of peptide wellness content have never made it to a Phase IIb trial. AOD-9604 did. It met the enrollment target. It completed the protocol. It simply did not meet the endpoint the trial was designed to test. The April 2026 removal from Category 2 is a regulatory change. The [FDA bulk drug substances safety framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) is the architecture within which any compounding-access question about AOD-9604 now sits — and that framework still requires a Category 1 review before licensed compounding becomes available. No such review has been scheduled. The gap between Category 2 removal and actual compounding access is the full distance from now to a review date that does not yet exist. That is where the evidence and the regulatory story both stand in May 2026.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.